AstraZeneca Results Presentation Deck
Year to date and Q3 2021: performance.
Oncology, CVRM and Respiratory & Immunology all delivered double digit growth
7
Oncology
CVRM
Respiratory &
Immunology
Rare Disease
Other medicines
Total revenue
excl. vaccine
Pandemic COVID-19 vaccine
Total revenue
Growth
across disease areas
YTD '21
$m
9,744
6,028
4,456
1,311
1,648
23,187
2,219
25,406
growth
%
Total revenue at actual exchange rates; changes at CER. EM = emerging markets.
16
10
12
n/m
(16)
17
n/m
28
Q3 '21
$m
3,383
2,086
1,486
1,311
550
8,816
1,050
9,866
growth
%
17
13
25
n/m
(28)
32
n/m
48
US
EM
- EM excl. China
- China
Growth
across geographies (excluding COVID-19 vaccine)
Europe
Established
Rest of World
Pandemic COVID-19 vaccine
Total revenue
YTD '21
$m
8,305
7,479
2,780
4,699
4,442
2,961
2,219
25,406
growth
%
29
10
14
12
12
n/m
28
Q3 '21
$m
3,471
2,508
1,018
1,490
1,753
1,084
1,050
9,866
growth
%
53
12
30
2
36
20
n/m
48
BView entire presentation